WO2024147111 - GLYCOENGINEERED POLYPEPTIDES TARGETING ANTI-NEUTROPHIL AUTOANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/147111
Publication Date
11.07.2024
International Application No.
PCT/IB2024/050112
International Filing Date
05.01.2024
Title **
[English]
GLYCOENGINEERED POLYPEPTIDES TARGETING ANTI-NEUTROPHIL AUTOANTIBODIES AND USES THEREOF
[French]
POLYPEPTIDES GLYCOMODIFIÉS CIBLANT DES AUTO-ANTICORPS ANTI-NEUTROPHILES ET LEURS UTILISATIONS
Applicants **
GLYCOERA AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
Inventors
KAUNDINYA, Ganesh
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
GANGULY, Tanmoy
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
FOLLADOR, Rainer
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
MALLY, Manuela
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
BACK, Jonathan Albert
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
MANNI, Michela
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
SIRENA, Dominique Nicolas
c/o GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil, CH
Priority Data
63/478,558
05.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3721 | |
| EPO | Filing, Examination | 36664 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 18210 |
Total: 59759 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to an anti-neutrophil autoantibody and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and/or nucleic acids encoding the same, as well as methods of making and using the same.[French]
La présente invention concerne des polypeptides glycomodifiés comprenant une première fraction contenant un ou plusieurs peptides qui se lient de manière spécifique à un auto-anticorps anti-neutrophile et une seconde fraction contenant un ou plusieurs glycanes conjugués à la première fraction au niveau d'un ou de plusieurs sites de glycosylation. La présente invention concerne également une séquence d'acide nucléique codant des polypeptides glycomodifiés de l'invention. La présente invention concerne en outre des compositions comprenant des polypeptides glycomodifiés et/ou des acides nucléiques codant ceux-ci, ainsi que des méthodes de production et d'utilisation de celles-ci.